Skip to content

Prospective evaluation of embolization assisted with pulsed dye laser in the treatment of CM-AVM

Prospective evaluation of embolization assisted with pulsed dye laser in the treatment of CM-AVM

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015696
Enrollment
Unknown
Registered
2018-04-15
Start date
2018-04-30
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CM-AVM

Interventions

Case series:Embolozation with PDL

Sponsors

Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 2-60 years; 2. With a typical clinical manifestation, coincidental imaging data including CT/MRI/ B ultrasonic diagnosis by DSA; 3. No symptom threatening life such as massive bleeding or heart failure in recent period; No serious underlying systemic disease especially in immune system, respiratory system and circulatory system; 4. To be able to and willingness to sign an inform consent form after fully understanding the therapeutic strategy and potential risks.

Exclusion criteria

Exclusion criteria: 1. With an age over 60 or less than two; 2. Without a typical clinical manifestation, or having not exactly characters of medical imaging; 3. The nidus was closely connection with intracranial abnormal vessel lesion; 4. Having symptoms threatening life needing to manage immediately; 5. Serious underlying systemic disease requiring treatment until illness either completes therapy or achieves clinical stablility on therapy for at least 6 months before enrolled the study. The systemic diseases include insufficient pulmonary functions(COPD, pneumonia, pulmonary fibrosis and asthma), insufficient cardiac and hepatorenal functions, infection, hemorrhagic tendency, immunologic disease(SLE, urticaria, HIV); 6. Accepting any therapy in the last 3 months including operation or embolization; 7. Refusing to sign an inform consent form after fully understanding the therapeutic strategy and potential risks; 8. Other contraindications of embolization with ethanol or PDL including pregnancy, lactation or combining with some other drugs like antitumor drug.

Design outcomes

Primary

MeasureTime frame
Clinical manisfestations;Imaging findings;

Countries

China

Contacts

Public ContactXindong Fan

Shanghai 9th People's Hospital, Shanghai Jiaotong University, School of Medicine

fanxindong@aliyun.com+86 021-2965666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026